ADAR1 Capital Management LLC Takes $374,000 Position in Moderna, Inc. (NASDAQ:MRNA)

ADAR1 Capital Management LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,000 shares of the company’s stock, valued at approximately $374,000.

Several other institutional investors have also added to or reduced their stakes in MRNA. FMR LLC grew its stake in shares of Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. State Street Corp lifted its stake in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its holdings in Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company’s stock worth $300,219,000 after purchasing an additional 171,774 shares in the last quarter. Wellington Management Group LLP grew its holdings in Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Moderna in the fourth quarter valued at about $163,833,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Morgan Stanley lowered their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Finally, Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus price target of $59.00.

Moderna Stock Down 2.4 %

MRNA stock opened at $25.11 on Monday. The firm’s 50-day simple moving average is $33.55 and its 200 day simple moving average is $42.61. The stock has a market cap of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a fifty-two week low of $23.76 and a fifty-two week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.